GeneDx Holdings
WGS· Services· Fiscal year ends in December
Katherine Stueland is the CEO of GeneDx Holdings and was paid $13.5M in FY2025 (Dec), up 206%.
Executives3
See all- 1Katherine StuelandChief Executive OfficerFY2025
- 2Kevin FeeleyChief Financial OfficerFY2025
- 3Bryan DechairoChief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allGeneDx Holdings paid its 3 named executives $21.8M in total in FY2025 (Dec). CEO Katherine Stueland was paid $13.5M of that.
| Name | |||
|---|---|---|---|
| Katherine StuelandChief Executive Officer | |||
| Kevin FeeleyChief Financial Officer | |||
| Bryan DechairoChief Operating Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers17
See allThe FY2025 (Dec) proxy of GeneDx Holdings names 17 peer companies for pay. Among GeneDx Holdings and these peers, CEO pay was 3rd highest of 10 and total shareholder return was the highest of 10.
3rd highest of 10in GeneDx Holdings and its pay peers, FY2025 (Dec) by CEO pay:
1st highest of 10in GeneDx Holdings and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Eli CasdinDirector · 5 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- Emily LeproustDirector · 5 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance (Chair)—Paid as an executive
- Joshua RuchDirector · 4 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance—Paid as an executive
- Richard C. Pfenniger, Jr.Director · 3 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Feb 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Feb 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Feb 23, 2024 | FY2023 |